Details
Stereochemistry | ACHIRAL |
Molecular Formula | C34H44N4O4 |
Molecular Weight | 572.7376 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCN(C1CCOCC1)C2=C(C)C(=CC(=C2)C3=CC=C(CN4CCOCC4)C=C3)C(=O)NCC5=C(C)C=C(C)NC5=O
InChI
InChIKey=NSQSAUGJQHDYNO-UHFFFAOYSA-N
InChI=1S/C34H44N4O4/c1-5-38(29-10-14-41-15-11-29)32-20-28(27-8-6-26(7-9-27)22-37-12-16-42-17-13-37)19-30(25(32)4)33(39)35-21-31-23(2)18-24(3)36-34(31)40/h6-9,18-20,29H,5,10-17,21-22H2,1-4H3,(H,35,39)(H,36,40)
Molecular Formula | C34H44N4O4 |
Molecular Weight | 572.7376 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 09:36:28 UTC 2023
by
admin
on
Sat Dec 16 09:36:28 UTC 2023
|
Record UNII |
Q40W93WPE1
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
637118
Created by
admin on Sat Dec 16 09:36:29 UTC 2023 , Edited by admin on Sat Dec 16 09:36:29 UTC 2023
|
||
|
FDA ORPHAN DRUG |
607017
Created by
admin on Sat Dec 16 09:36:29 UTC 2023 , Edited by admin on Sat Dec 16 09:36:29 UTC 2023
|
||
|
FDA ORPHAN DRUG |
508415
Created by
admin on Sat Dec 16 09:36:29 UTC 2023 , Edited by admin on Sat Dec 16 09:36:29 UTC 2023
|
||
|
NCI_THESAURUS |
C274
Created by
admin on Sat Dec 16 09:36:29 UTC 2023 , Edited by admin on Sat Dec 16 09:36:29 UTC 2023
|
||
|
EU-Orphan Drug |
EU/3/18/2004
Created by
admin on Sat Dec 16 09:36:29 UTC 2023 , Edited by admin on Sat Dec 16 09:36:29 UTC 2023
|
||
|
FDA ORPHAN DRUG |
544416
Created by
admin on Sat Dec 16 09:36:29 UTC 2023 , Edited by admin on Sat Dec 16 09:36:29 UTC 2023
|
||
|
FDA ORPHAN DRUG |
578417
Created by
admin on Sat Dec 16 09:36:29 UTC 2023 , Edited by admin on Sat Dec 16 09:36:29 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB178719
Created by
admin on Sat Dec 16 09:36:29 UTC 2023 , Edited by admin on Sat Dec 16 09:36:29 UTC 2023
|
PRIMARY | |||
|
DB12887
Created by
admin on Sat Dec 16 09:36:29 UTC 2023 , Edited by admin on Sat Dec 16 09:36:29 UTC 2023
|
PRIMARY | |||
|
Q40W93WPE1
Created by
admin on Sat Dec 16 09:36:29 UTC 2023 , Edited by admin on Sat Dec 16 09:36:29 UTC 2023
|
PRIMARY | |||
|
DTXSID201025831
Created by
admin on Sat Dec 16 09:36:29 UTC 2023 , Edited by admin on Sat Dec 16 09:36:29 UTC 2023
|
PRIMARY | |||
|
66558664
Created by
admin on Sat Dec 16 09:36:29 UTC 2023 , Edited by admin on Sat Dec 16 09:36:29 UTC 2023
|
PRIMARY | |||
|
5380
Created by
admin on Sat Dec 16 09:36:29 UTC 2023 , Edited by admin on Sat Dec 16 09:36:29 UTC 2023
|
PRIMARY | |||
|
1403254-99-8
Created by
admin on Sat Dec 16 09:36:29 UTC 2023 , Edited by admin on Sat Dec 16 09:36:29 UTC 2023
|
PRIMARY | |||
|
Tazemetostat
Created by
admin on Sat Dec 16 09:36:29 UTC 2023 , Edited by admin on Sat Dec 16 09:36:29 UTC 2023
|
PRIMARY | |||
|
FG-162
Created by
admin on Sat Dec 16 09:36:29 UTC 2023 , Edited by admin on Sat Dec 16 09:36:29 UTC 2023
|
PRIMARY | |||
|
m12194
Created by
admin on Sat Dec 16 09:36:29 UTC 2023 , Edited by admin on Sat Dec 16 09:36:29 UTC 2023
|
PRIMARY | |||
|
9963
Created by
admin on Sat Dec 16 09:36:29 UTC 2023 , Edited by admin on Sat Dec 16 09:36:29 UTC 2023
|
PRIMARY | |||
|
Q40W93WPE1
Created by
admin on Sat Dec 16 09:36:29 UTC 2023 , Edited by admin on Sat Dec 16 09:36:29 UTC 2023
|
PRIMARY | |||
|
C107506
Created by
admin on Sat Dec 16 09:36:29 UTC 2023 , Edited by admin on Sat Dec 16 09:36:29 UTC 2023
|
PRIMARY | |||
|
100000164315
Created by
admin on Sat Dec 16 09:36:29 UTC 2023 , Edited by admin on Sat Dec 16 09:36:29 UTC 2023
|
PRIMARY | |||
|
2274378
Created by
admin on Sat Dec 16 09:36:29 UTC 2023 , Edited by admin on Sat Dec 16 09:36:29 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
biochemical assay
IC50
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
BINDER->LIGAND |
In vitro, tazemetostat is 87.7 to 91.1% bound to human plasma proteins over the concentration range of 1 to 30 M.
BINDING
|
||
|
TRANSPORTER -> SUBSTRATE |
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
MAJOR
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE INACTIVE -> PARENT |
MAJOR
|
||
|
METABOLITE -> PARENT |
|
||
|
METABOLITE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
|
|||
blood-to-plasma ratio | PHARMACOKINETIC |
|
|
|||
Volume of Distribution | PHARMACOKINETIC |
|
|
|||
Tmax | PHARMACOKINETIC |
|
SINGLE ORAL DOSE ADMINISTRATION |
|
||